Triple test

The triple test is a maternal blood screening test that is conducted during pregnancy to assess the risk of certain genetic conditions in the developing fetus. It is typically performed during the second trimester, between the 15th and 20th weeks of pregnancy.

Components of the Triple Test

The triple test measures the levels of three specific substances in the mother's blood:

• Alpha-fetoprotein (AFP): A protein produced by the fetal liver that is present in the amniotic fluid and crosses into the mother's bloodstream.
• Human chorionic gonadotropin (hCG): A hormone produced by the placenta during pregnancy.
• Unconjugated estriol (uE3): An estrogen produced by both the fetus and the placenta.

Purpose and Interpretation

The primary purpose of the triple test is to screen for chromosomal abnormalities such as Down syndrome (trisomy 21) and Edward's syndrome (trisomy 18). It can also help detect neural tube defects such as spina bifida.

The results of the triple test are interpreted based on the levels of the three substances measured, along with the mother's age, weight, ethnicity, and gestational age of the fetus. The test provides a risk assessment rather than a definitive diagnosis. If the test indicates a high risk of abnormalities, further diagnostic testing, such as amniocentesis or chorionic villus sampling, may be recommended.

Advantages and Limitations

The triple test is a non-invasive screening tool that poses no risk to the fetus. However, it is important to note that it is not a diagnostic test and can only indicate the likelihood of certain conditions. False positives and false negatives can occur, which is why it is often used in conjunction with other screening methods.

Related Pages

• Prenatal testing
• Quad screen
• Non-invasive prenatal testing

References

• "Prenatal Screening Tests: Types and Diagnosis." American Pregnancy Association. Retrieved from .
• "Triple Test." National Health Service (NHS). Retrieved from .

External Links

• [American College of Obstetricians and Gynecologists (ACOG) Guidelines on Prenatal Screening](https://www.acog.org/clinical/clinical-guidance/practice-bulletin/articles/2020/06/screening-for-fetal-chromosomal-abnormalities)

Diagram of prenatal Down syndrome screening algorithm.